Literature DB >> 2521266

The myocardium in congestive heart failure.

A M Katz1.   

Abstract

It is now apparent that the myocardium in patients with congestive heart failure (CHF) is not normal, because important structural and molecular changes modify function in these hearts. It appears likely that the myocardium in these patients with CHF becomes unable to provide enough chemical energy to meet its mechanical requirements. If this interpretation is correct, the resulting condition of "energy starvation" would have several important implications for therapy. For example, inotropic stimulation, by increasing energy expenditure, could contribute to the progressive myocardial cell death that characterizes end-stage cardiac hypertrophy. Conversely, the reduction in myocardial contractility that develops in the chronically over-loaded heart reduces myocardial energy expenditure, and changes in the expression of myosin isoforms improve cardiac efficiency. Therefore, an important goal of therapy in the patient with CHF is to reduce energy expenditure by unloading the failing heart and, in some cases, by administration of negative inotropic drugs.

Entities:  

Mesh:

Year:  1989        PMID: 2521266     DOI: 10.1016/0002-9149(89)90386-x

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  12 in total

Review 1.  The management of conditioned nutritional requirements in heart failure.

Authors:  Marc L Allard; Khursheed N Jeejeebhoy; Michael J Sole
Journal:  Heart Fail Rev       Date:  2006-03       Impact factor: 4.214

2.  Prognostic significance of myocardial energy expenditure and myocardial efficiency in patients with heart failure with reduced ejection fraction.

Authors:  Mehmet S Cetin; Elif H Ozcan Cetin; Ugur Canpolat; Hatice Sasmaz; Ahmet Temizhan; Sinan Aydogdu
Journal:  Int J Cardiovasc Imaging       Date:  2017-08-14       Impact factor: 2.357

Review 3.  Medical therapy for acute decompensated heart failure: what recent clinical trials have taught us about diuretics and vasodilators.

Authors:  Catherine Marti; Robert Cole; Andreas Kalogeropoulos; Vasiliki Georgiopoulou; Javed Butler
Journal:  Curr Heart Fail Rep       Date:  2012-03

4.  Impairment of subendocardial perfusion reserve and oxidative metabolism in nonischemic dilated cardiomyopathy.

Authors:  Susan P Bell; Douglas W Adkisson; Henry Ooi; Douglas B Sawyer; Mark A Lawson; Marvin W Kronenberg
Journal:  J Card Fail       Date:  2013-10-29       Impact factor: 5.712

5.  Human myocardial ATP content and in vivo contractile function.

Authors:  R C Starling; D F Hammer; R A Altschuld
Journal:  Mol Cell Biochem       Date:  1998-03       Impact factor: 3.396

Review 6.  Left ventricular dilatation and failure post-myocardial infarction: pathophysiology and possible pharmacologic interventions.

Authors:  B G Firth; P M Dunnmon
Journal:  Cardiovasc Drugs Ther       Date:  1990-10       Impact factor: 3.727

Review 7.  Risks and benefits of the treatment of heart failure. Current status.

Authors:  J F Moran
Journal:  Drug Saf       Date:  1991 Jul-Aug       Impact factor: 5.606

Review 8.  Use of milrinone in cardiac surgical patients.

Authors:  K M Sherry; T J Locke
Journal:  Cardiovasc Drugs Ther       Date:  1993-08       Impact factor: 3.727

9.  Role of metabolic therapy in cardiovascular disease.

Authors:  F Rengo; P Abete; P Landino; D Leosco; F Covelluzzi; D Vitale; V Fedi; N Ferrara
Journal:  Clin Investig       Date:  1993

10.  Metformin rescues the myocardium from doxorubicin-induced energy starvation and mitochondrial damage in rats.

Authors:  Abdelkader E Ashour; Mohamed M Sayed-Ahmed; Adel R Abd-Allah; Hesham M Korashy; Zaid H Maayah; Hisham Alkhalidi; Mohammed Mubarak; Abdulqader Alhaider
Journal:  Oxid Med Cell Longev       Date:  2012-05-10       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.